Eton Pharmaceuticals Future Growth
Future criteria checks 5/6
Eton Pharmaceuticals is forecast to grow earnings and revenue by 57.6% and 27.3% per annum respectively while EPS is expected to grow by 57.6% per annum.
Key information
57.6%
Earnings growth rate
57.6%
EPS growth rate
| Pharmaceuticals earnings growth | 23.5% |
| Revenue growth rate | 27.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Sep 2024 |
Recent future growth updates
Recent updates
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 71 | 18 | N/A | N/A | 1 |
| 12/31/2025 | 50 | 7 | 10 | 10 | 2 |
| 12/31/2024 | 37 | -4 | 0 | 0 | 2 |
| 6/30/2024 | 31 | -7 | -3 | 0 | N/A |
| 3/31/2024 | 34 | 1 | 3 | 6 | N/A |
| 12/31/2023 | 32 | -1 | 6 | 7 | N/A |
| 9/30/2023 | 33 | 2 | 9 | 9 | N/A |
| 6/30/2023 | 29 | 0 | 5 | 7 | N/A |
| 3/31/2023 | 24 | -6 | -1 | 2 | N/A |
| 12/31/2022 | 21 | -9 | 2 | 5 | N/A |
| 9/30/2022 | 19 | -9 | -9 | -3 | N/A |
| 6/30/2022 | 16 | -12 | -8 | -4 | N/A |
| 3/31/2022 | 12 | -12 | -10 | -7 | N/A |
| 12/31/2021 | 22 | -2 | -8 | -5 | N/A |
| 9/30/2021 | 16 | -11 | -7 | -7 | N/A |
| 6/30/2021 | 15 | -11 | -9 | -9 | N/A |
| 3/31/2021 | 12 | -14 | -11 | -11 | N/A |
| 12/31/2020 | 0 | -28 | -22 | -22 | N/A |
| 9/30/2020 | 0 | -23 | -20 | -19 | N/A |
| 6/30/2020 | 1 | -21 | -18 | -17 | N/A |
| 3/31/2020 | 1 | -20 | -20 | -18 | N/A |
| 12/31/2019 | 1 | -18 | -20 | -18 | N/A |
| 9/30/2019 | 1 | -42 | -17 | -16 | N/A |
| 6/30/2019 | 1 | -40 | -16 | -15 | N/A |
| 3/31/2019 | 1 | -41 | -14 | -13 | N/A |
| 12/31/2018 | N/A | -37 | -8 | -8 | N/A |
| 9/30/2018 | N/A | -18 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: ETON is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ETON is expected to become profitable in the next 3 years.
Revenue vs Market: ETON's revenue (27.3% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: ETON's revenue (27.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETON's Return on Equity is forecast to be high in 3 years time